Pages

Wednesday, October 05, 2016

EXCLUSIVE: Preferred Pharmacy Networks Are Back in 85% of the 2017 Medicare Part D Plans

The Centers for Medicare & Medicaid Services (CMS) just released the initial data on the 2017 Medicare Part D plans. Our exclusive analysis reveals that preferred cost sharing pharmacy networks are back.

For 2017, 85% of Medicare Part D regional prescription drug plans (PDP) will have a preferred network. That’s comparable to the figures from the past three years.

Below, I provide historical data on preferred networks’ growth and then identify 2017’s top plans. The two largest companies—UnitedHealthcare and Humana—offer only preferred networks for 2017. Both companies are also offering co-branded plans with retail chains: United Healthcare with Walgreens, and Humana with Walmart.

Such narrow pharmacy networks—either preferred or limited models—are now an unstoppable and widely accepted element of benefit design. Pharmacies will continue to see their prescription profit margins terminated. In a future post, I’ll be back to examine which chains and independents are participating in the preferred networks. A DOWNLOAD FROM SKYNET

A preferred network gives consumers a choice of pharmacy. It also provides them with financial incentives to use the pharmacies that offer lower costs or greater control to the payer. A consumer with a preferred network benefit design retains the option of using any pharmacy in the network. However, a consumer’s out-of-pocket expenses will be higher at a non-preferred pharmacy.

Preferred network models have grown most rapidly within the Medicare Part D program, where CMS now calls them preferred cost sharing networks. CMS refers to the pharmacies in such a network as preferred cost-sharing pharmacies.

I included the Cigna-HealthSpring Rx Secure and Rx Secure-Extra plans that are under sanction as of September 6, 2016. (This CMS memo explain the situation.) The CMS data provide information for these sanctioned plans, but the plans can’t accept new enrollees. These PDPs have preferred pharmacy networks and account for 68 plans.

My final sample included 71 plans, which operate 746 regional PDPs. Seventeen plans are being offered in all 34 regions, for a total of 578 PDPs (=17*34). The other 54 plans are operating in anywhere from 1 to 33 regions and account for 168 regional PDPs.

COME WITH ME IF YOU WANT TO PROFIT

In 2017, preferred cost-sharing networks continue to dominate the Part D landscape. The chart shows the growth of preferred networks in stand-alone prescription drug plans. In 2011, only 7% of total regional PDPs had a preferred network. In 2017, 85% plans have preferred networks.

[Click to Enlarge]

Over the past few years, the share of plans with a preferred network has remained fairly steady. The total number of plans, however, has declined significantly, from 1,1,69 in 2014 to 746 in 2017. The number of plans with preferred networks has also declined, from 841 in 2014 to 633 in 2017.

HASTA LA VISTA, OPEN NETWORKS!

Here is a summary of the major companies that offer PDPs in 2017, along with the split of preferred cost sharing vs. open pharmacy networks.

[Click to Enlarge]

Due to consolidation and exit, there are fewer major plan sponsors. Here are the 2017 highlights from the major companies:

UnitedHealthcare is offering four plans in 2017: two AARP-branded plans, a co-branded AARP MedicareRx Walgreens plan, and Symphonix Value Rx. The AARP-branded plans have preferred networks with 24,000 pharmacies, while the AARP-Walgreens plan has only 8,000 Walgreens and Duane Reade stores as preferred pharmacies. Click here to view the fact sheet about this new Walgreens plan.

Humana is offering the same three plans that it has for the past three years: Humana Enhanced, Humana Preferred Rx Plan (its original plan with Walmart), and the co-branded Humana Walmart Rx Plan. All three plans have a preferred network and are being offered in all 34 regions.

Last year, Wellcare switched its three plans from preferred cost sharing to open networks. Those plans will have open networks in 2017, too. Wellcare is now the largest sponsor of open network plans and accounts for 60% of them.

As I note above, the two Cigna-HealthSpring plans are under sanction and can’t accept new enrollees. Both plans have preferred cost-sharing networks.

More payers will use tightly controlled pharmacy networks as they seek additional drug spending savings. The reduction in pharmacy profits is the biggest source of cost savings from narrow networks, because pharmacies have been willing to accept reduced reimbursement rates in exchange for participation in a preferred or limited network. For the economics of narrow network models, see Chapter 7 of our 2016 Economic Report on Retail, Mail, and Specialty Pharmacies. Section 7.2.4. (page 125) explains the controversial direct and indirect remuneration (DIR) fees.

DISCLAIMERThe analyses on this website are based on information and data that are in the public domain. Any conclusions, findings, opinions, or recommendations are based on our own experienced and professional judgment and interpretations given the information available. While all information is believed to be reliable at the time of writing, the information provided here is for reference use only and does not constitute the rendering of legal, financial, commercial, or other professional advice by Pembroke Consulting, Inc. or the author. Any reliance upon the information is at your own risk, and Pembroke Consulting, Inc. and the author shall not be responsible for any liability arising from or related to the use or accuracy of the information in any way. Pembroke Consulting, Inc. does not make investment recommendations, on this website or otherwise. Nothing on this website should be interpreted as an opinion by Pembroke Consulting, Inc. or the author on the investment prospects of specific companies.

The comments contained on this site come from members of the public and do not necessarily reflect the views of Pembroke Consulting or the author. Neither Pembroke Consulting nor the author endorse or approve of their content. Pembroke Consulting and the author reserve the right to remove or block comments, but are under no obligation to explain individual moderation decisions.

The public domain use of our materials includes linking to our website. You do not need to obtain special permission to link to the Drug Channels site.

The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., or any of its employees.